Abstract Number: 287 • 2017 ACR/ARHP Annual Meeting
Anti-TNF Agents Induce Alternative Macrophages
Background/Purpose: Macrophages contribute to the pathogenesis of rheumatoid arthritis (RA). They can display various states of activation or « polarization », characterized by distinct functions…Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting
Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…Abstract Number: 423 • 2017 ACR/ARHP Annual Meeting
Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden
Background/Purpose: Pain is a dominant and debilitating feature of RA, but while a lot of focus has been put on the occurrence and management of…Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting
Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial
Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…Abstract Number: 2881 • 2017 ACR/ARHP Annual Meeting
Pre-Existing Psoriasis Is Predictive for Clinical Relapse after Drug-Free Remission Induced By Therapy with Golimumab in Early Peripheral Spondyloarthritis
Background/Purpose: The use of new treatment strategies in early stages of spondyloarthritis (SpA) makes it possible to achieve remission or low disease activity in more…Abstract Number: 543 • 2017 ACR/ARHP Annual Meeting
Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune chronic disease with disability and deforms joints. After the introduction of biological therapies the prognosis of…Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting
MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…Abstract Number: 546 • 2017 ACR/ARHP Annual Meeting
Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) have been widely used in patients who failed conventional DMARDs in the treatment of rheumatoid arthritis (RA). While most…Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…Abstract Number: 550 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
Background/Purpose: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody targeted against the interleukin-6 receptor that was approved to treat rheumatoid arthritis (RA) in the EU…Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…Abstract Number: 606 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Background/Purpose: Pooled safety data from secukinumab psoriasis (PSO) and psoriatic arthritis (PsA) clinical trial programs after ~1 year of exposure have been reported previously.1, 2…Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting
Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 29
- Next Page »